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Summary
Background More than 70 million people worldwide are estimated to have hepatitis C virus (HCV) infection. Emerging 
evidence indicates an association between HCV and atherosclerotic cardiovascular disease. We aimed to determine 
the association between HCV and cardiovascular disease, and estimate the national, regional, and global burden of 
cardiovascular disease attributable to HCV.
Methods For this systematic review and meta-analysis, we searched MEDLINE, Embase, Ovid Global Health, and 
Web of Science databases from inception to May 9, 2018, without language restrictions, for longitudinal studies that 
evaluated the risk ratio (RR) of cardiovascular disease in people with HCV compared with those without HCV. 
Two investigators independently reviewed and extracted data from published reports. The main outcome was 
cardiovascular disease, defined as hospital admission with, or mortality from, acute myocardial infarction or stroke. 
We calculated the pooled RR of cardiovascular disease associated with HCV using a random-effects model. 
Additionally, we calculated the population attributable fraction and disability-adjusted life-years (DALYs) from HCV-
associated cardiovascular disease at the national, regional, and global level. We also used age-stratified and sex-
stratified HCV prevalence estimates and cardiovascular DALYs for 100 countries to estimate country-level burden 
associated with HCV. This study is registered with PROSPERO, number CRD42018091857.
Findings Our search identified 16 639 records, of which 36 studies were included for analysis, including 341 739 people 
with HCV. The pooled RR for cardiovascular disease was 1·28 (95% CI 1·18–1·39). Globally, 1·5 million 
(95% CI 0·9–2·1) DALYs per year were lost due to HCV-associated cardiovascular disease. Low-income and middle-
income countries had the highest disease burden with south Asian, eastern European, north African, and Middle 
Eastern regions accounting for two-thirds of all HCV-associated cardiovascular DALYs.
Interpretation HCV infection is associated with an increased risk of cardiovascular disease. The global burden of 
cardiovascular disease associated with HCV infection was responsible for 1·5 million DALYs, with the highest burden 
in low-income and middle-income countries.
Funding British Heart Foundation and Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Globally, more than 70 million people are estimated to 
have hepatitis C virus (HCV) infection.1 Prevalence of 
HCV is particularly high in the eastern Mediterranean 
region and Europe, where approximately 2·3% and 1·5% 
of the general population have HCV infection, 
respectively.1 In the USA, the estimated prevalence of 
past or current HCV infection is 1·4%, affecting 
4·6 million people, of whom at least 3·5 million have 
active HCV infection (1% of the general population).2 
The number of new incident cases of HCV infections in 
the USA has been increasing since 2010.3 
After acute HCV infection, most patients develop 
chronic infection.4 Usually, these patients remain 
asymptomatic, with less than a third progressing to liver 
cirrhosis in the subsequent 20–30 years.4 Although 
mortality due to cirrhosis and hepatocellular carcinoma 
are well recognised long-term complications of chronic 
HCV infection,5,6 patients with chronic infection are also 
at increased risk of non-liver-related mortality, including 
cancer and circulatory death.7
Atherosclerotic cardiovascular disease is the most 
common cause of death worldwide and the burden of 
disease is projected to rise substantially over the next few 
decades, particularly in low-income and middle-income 
countries (LMICs).8 HCV transmission is also projected 
to rise considerably in LMICs due to unsafe health-care 
practices and injection drug use.9–11 Published data12–14 
suggest that the long period of chronic HCV infection 
might lead to the development of atherosclerotic 
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cardiovascular disease because of derangements in 
metabolic pathways and chronic inflammation. However, 
the direction and strength of the association between 
HCV infection and cardiovascular disease remains 
uncertain.15–19
Our study aimed to determine the association between 
HCV infection and the risk of cardiovascular disease to 
establish the global burden of cardiovascular disease 
attributable to HCV. 
Methods
Search strategy and selection criteria
We searched MEDLINE, EMBASE, Ovid Global Health, 
and Web of Science from database inception to May 9, 
2018, for original peer-reviewed articles using the search 
terms “myocardial infarction”, “stroke”, “cerebrovascular 
disease”, “cardiovascular disease”, and “hepatitis C” with 
no language restrictions. Full search terms are in the 
appendix (pp 2, 3). Additionally, we manually searched 
relevant review articles and bibliographic reference lists 
of studies selected for inclusion in our meta-analysis. 
We included all longitudinal studies (case-control 
studies, cohort studies, and randomised controlled trials) 
that reported risk ratios (RRs) for hospital admission due 
to atherosclerotic cardiovascular disease or cardiovascular 
mortality in people with HCV compared with people 
without HCV. When there were multiple publications 
using data from the same cohort, we selected the article 
that reported the longest follow-up period. Detailed full-
text review and data extraction was done independently 
by at least two investigators (KKL, DS, RB, or MA) and 
any disagreements were resolved by a third investigator 
(ASVS). We contacted authors for additional data or 
clarification if required. This study was done in 
accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (appendix pp 4, 5).20 The study protocol is 
available online.
For studies that stratified the study population 
according to the presence of HCV RNA viraemia, we 
used the RR estimates pertaining to individuals who 
were HCV RNA positive. We defined a cardiovascular 
event as hospital admission with, or mortality from, 
acute myocardial infarction or stroke. Studies that 
evaluated a composite of acute cardiovascular events that 
included myocardial infarction or stroke but were not 
exclusive to these conditions were also included. For 
studies that stratified stroke events into haemorrhagic 
and ischaemic strokes, we included only ischaemic 
strokes in the analysis because haemorrhagic strokes 
have distinct patho physiological mechanisms that are 
unrelated to atherosclerosis.21 
Data analysis
We extracted RR estimates comparing cardiovascular 
events in people with HCV versus those without HCV 
from published reports using a standardised data 
extraction sheet. We estimated pooled RRs with 
95% CIs. Since this outcome was relatively uncommon, 
we pooled studies that reported odds ratio and RR. We 
also assumed independence between risk estimates for 
different endpoints reported within studies, consistent 
with our previous analysis.22 We did a subgroup analysis 
stratified by outcome, HIV co-infection, publication 
year, risk of bias, definition of outcome event, and 
geographical location. 
Two independent investigators (KKL and DS) assessed 
individual studies for risk of bias, using the degree of 
adjustment for confounders as the primary domain, and 
any disagreements were adjudicated by a third investigator. 
Studies that had adjusted for age, sex, and at least one 
other confounder were classified as being at low risk of 
bias. Studies that adjusted for fewer confounders than this 
were classified as moderate or high risk: studies that 
adjusted for either age or sex without any other con-
founders were classified as moderate risk of bias and 
Research in context
Evidence before this study 
We searched PubMed from database inception to Jan 1, 2018, 
for systematic reviews and meta-analyses evaluating the 
association between hepatitis C virus (HCV) infection and 
atherosclerotic cardiovascular disease using the search terms 
“myocardial infarction”, “stroke”, “cerebrovascular disease”, 
“cardiovascular disease”, and “hepatitis C”. We found no studies 
that assessed the risk of cardiovascular disease or calculated the 
burden from all major atherosclerotic cardiovascular events 
associated with hepatitis C. Previous meta-analyses have 
evaluated the association between HCV infection and stroke 
and surrogate markers of subclinical atherosclerotic disease. 
Added value of this study 
To our knowledge, our study is the first meta-analysis to 
investigate the risk of major atherosclerotic cardiovascular 
disease in people with HCV infection and to estimate the 
burden of atherosclerotic cardiovascular disease attributed to 
HCV infection at the global, regional, and national level. 
Implication of all the available evidence
Our findings show that people with HCV infection have a 
higher risk of cardiovascular disease than those without. 
The global burden of cardiovascular disease attributable to 
HCV accounted for a substantial number of disability-adjusted 
life-years in 2015, and the majority of the burden was borne 
by low-income and middle-income countries. These finding 
highlights the importance of public health strategies to 
eradicate HCV infection to reduce the burden of not only 
hepatic, but extrahepatic complications (such as 
cardiovascular disease), especially in regions with high HCV 
prevalence.
See Online for appendix
For study protocol see https://
www.crd.york.ac.uk/prospero/
display_record.
php?RecordID=91857
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those that did not adjust for both age or sex were classified 
as high risk of bias. We did the subgroup analysis stratified 
by risk of bias.
We estimated the burden of cardiovascular disease 
attributable to HCV at the national, regional, and global 
level. We obtained 2015 global prevalence estimates of 
viraemic HCV (HCV RNA positive) for 100 countries 
from the Polaris Observatory, with estimates stratified by 
Global Burden of Disease region.23 These 100 countries 
represent more than 85% of the global population and 
where more than 89% of all HCV viral infections (HCV 
RNA positive) are estimated to occur worldwide.23 The 
national prevalence estimates obtained were age-specific 
and sex-specific. We obtained age-specific and sex-specific 
disability-adjusted life-year (DALY) estimates for cardio-
vascular disease (DALYs due to ischaemic heart disease 
and stroke) for all adults aged older than 20 years in 2015 
from the Institute of Health Metrics and Evaluation.24 The 
extraction databases from the systematic review and the 
data from the Polaris Observatory and Institute of Health 
Metrics and Evaluation used to derive the pooled 
estimates and the burden estimates alongside the R code 
script are available online.
We estimated the population attributable risk fraction 
at the national, regional, and global level using the pooled 
RR for cardiovascular disease in patients with hepatitis C 
and the prevalence estimates of HCV. The population 
attributable fraction (PAF) for cardiovascular disease 
attributable to HCV was calculated as described 
previously:25,26
We then used national, regional, and global level 
attributable fractions to calculate the burden as previously 
described (appendix pp 6–10): 
DALYs attributable to HCV=Cardiovascular DALYs × PAF
We provided estimates of PAF and burden in 5-year 
age groups and presented data graphically using a linear 
model to interpolate the intervening years. We further 
provided burden estimates by income of nation stratified 
by high-income versus LMICs. National income status 
was defined according to the 2018 World Bank 
classification.27
We anticipated heterogeneity in the RRs across studies 
because of differences in study design, patient population, 
geographical location, statistical methods, and adjustment 
for confounders. We pooled RRs using a random effects 
model to account for within and between study hetero-
geneity. We assessed heterogeneity in the pooled meta-
estimate of the RR using the I² statistic. We assessed 
publication bias using visual inspection of funnel plots of 
the RR estimates and using Egger’s regression test for 
asymmetry.28 We corrected for asymmetry using Duval and 
Tweedie’s trim and fill method.29 Full statistical methods 
are in the appendix (pp 6–10). All analyses were done using 
R (version 3.4.1). A two-sided p value of less than 0·05 was 
considered to indicate statistical significance. 
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
We identified 16 650 articles, of which 2270 were 
duplicates (figure 1). 343 full-text articles were assessed 
for eligibility. After full-text review, 36 studies,7,30–64 which 
provided 47 estimates, were included in our analyses 
(table). These studies included 341 739 people with HCV. 
31 (86%) of 36 studies were done in North America, 
Europe, and east Asia. Only two studies30,31 originated 
from LMICs. Most studies used the International 
Classification of Diseases coding or physician diagnosis 
to define the outcome events.
24 studies defined HCV infection as anti-HCV antibody 
seropositivity, nine studies used detectable HCV RNA 
levels, and three studies did not explicitly define their 
approach (table). Overall, the meta-analysis showed that 
Figure 1: Study selection
16 639 records identified by database search
11 additional records identified 
 via bibliographic search
14 380 records identified for title and abstract screening
14 037 articles excluded
2270 duplicates removed
343 full-text articles assessed for eligibility
307 excluded after full-text 
 screening
 83 different study design
 or review paper
 62 wrong outcomes
 53 abstract only
 46 wrong patient 
 population
 35 duplicate articles
 15 wrong comparator
 11 insufficient data
    2 duplicates
36 studies included in quantitative synthesis
For more on the Polaris 
Observatory see http://
polarisobservatory.org/
For the extraction databases, 
data used to derive pooled 
estimates, burden estimates, 
and R code script see https://
github.com/kk-lee/hcv
Population attributable fraction =
Prevalence × (RR – 1)
1 + (Prevalence × RR)
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Cohort 
name
Country or 
region
Study 
type
Data source Participants, 
n
Events, 
n
Men, n 
(%) 
Mean age 
at baseline, 
years
Study 
period
Hepatitis C 
virus status
Outcome Outcome 
definition
Heo et al, 
201833
·· USA Cohort 
study
Organ Procurement and 
Transplant Network
2728 117 1996 
(73%)
50·9 2004–14 Seropositive Cardiovascular 
disease
Undefined
Alvaro-Meca 
et al, 201734
·· Spain Case-
control 
study
Spanish Minimum Basic 
Data Set
4091 369 3248 
(79%)
45 1997–2013 Seropositive Stroke* ICD-9
Butt et al, 
201735
ERCHIVES USA Cohort 
study
Veterans Health 
Administration
171 726 5949 171 726 
(100%)
54 2001–15 Viraemic Myocardial 
infarction
ICD-9
Chew et al, 
201736
ERCHIVES USA Cohort 
study
Veterans Health 
Administration
168 256 11 753 168 256 
(100%)
55 2001–14 Seropositive Cardiovascular 
disease
ICD-9
Goodkin et al, 
201730
DOPPS Multiple† Cohort 
study
Hospital records 76 689 6790 45 016 
(59%)
62·5 1996–2015 Seropositive Cardiovascular 
disease, 
myocardial 
infarction, stroke
Undefined
Kovari et al, 
201737
·· Switzerland Cohort 
study
Swiss HIV Cohort Study 5006 143 3624 
(72%)
50 1994–2014 Seropositive Cardiovascular 
disease*
Physician 
diagnosis
Piazza et al, 
201638
·· USA Cohort 
study
Hospital records 143 19 101 
(71%)
55 2005–10 Undefined Cardiovascular 
disease
Undefined
Fernandez-
Montero et al, 
201539
·· Spain Cohort 
study
Hospital register 1066 29 842 
(79%)
42·7 2004–15 Viraemic Cardiovascular 
disease† 
Physician 
diagnosis
Tsai et al, 
201540
NHIRD–HCV Taiwan Cohort 
study
National Health 
Insurance Research 
Database
69 915 848 35 936 
(51%)
54·7 1998–2008 Undefined Myocardial 
infarction
Undefined
Vajdic et al, 
201541
·· Australia Cohort 
study
Pharmaceutical Drugs 
of Addiction System
29 571 122 20 403 
(69%)
26 1993–2007 Seropositive Cardiovascular 
disease
ICD-9, 
ICD-10
Enger et al, 
201442
ORD USA Cohort 
study
Optum Research 
Database (insurance 
plans)
90 931 534 56 740 
(62%)
49 2000–06 Seropositive Myocardial 
infarction, stroke
ICD-9
Gillis et al, 
201443
OCS Canada Cohort 
study
Clinic register 4152 167 3483 
(84%)
36 1995–2011 Seropositive Cardiovascular 
disease† 
Physician 
diagnosis
Hsu et al, 
201444
·· Taiwan Cohort 
study
National Health 
Insurance Research 
Database
7055 429 4599 
(65%)
54·9 2003–11 Seropositive Myocardial 
infarction, stroke
ICD-9
Pothineni 
et al, 201445
UAMS USA Cohort 
study
Enterprise Data 
Warehouse at University 
of Arkansas for Medical 
Sciences
23 050 951 12 631 
(55%)
50·9 2001–13 Viraemic Cardiovascular 
disease
ICD-9
Tripathi et al, 
201446
·· USA Cohort 
study
Medicaid 13 632 1284 7661 
(56%)
38 1994–2011 Seropositive Cardiovascular 
disease
ICD-9
Womack et al, 
201447
Veterans 
Aging 
Cohort 
Study–
virtual 
cohort
USA Cohort 
study
Veterans Health 
Administration, 
Medicare, Medicaid, and 
Quality Enhancement 
Research Initiative in 
ischaemic heart disease
2187 86 0 43·6 2003–09 Seropositive Cardiovascular 
disease*
ICD-9
Adinolfi et al, 
201348
·· Italy Case-
control 
study
Hospital records 820 123 524 
(64%)
76 2010–12 Seropositive Stroke Physician 
diagnosis
Hsu et al, 
201349
LHID2000 Taiwan Cohort 
study
Longitudinal Health 
Insurance Database 
2000
15 565 NR 8078 
(52%)
Not 
reported
2004–07 Viraemic Stroke ICD-9
Younossi et al, 
201350
NHANES III USA Cohort 
study
National Health and 
Nutrition Examination 
Survey
8985 NR 4178 
(46%)
Not 
reported
1988–2006 Viraemic Cardiovascular 
disease
ICD-10
Campbell et al, 
201251
·· UK Cohort 
study
Hospital records 4068 32 4068 
(100%)
36·5 2004–09 Seropositive Cardiovascular 
disease*
Physician 
diagnosis
Carrieri et al, 
201252
APROCO-
COPILOTE
France Cohort 
study
Medical questionnaires 1154 49 900 
(78%)
37·7 1997–2010 Seropositive Cardiovascular 
disease* 
ICD-10
(Table continues on next page)
Articles
798 www.thelancet.com/gastrohep   Vol 4   October 2019
individuals with HCV had a higher risk of cardiovascular 
disease than individuals without HCV (pooled RR 1·28, 
95% CI 1·18–1·39; figure 2). When stratified by outcome 
the risk ratio was 1·13 (95% CI 1·00–1·28) for myocardial 
infarction, 1·38 (1·19–1·60) for stroke, and 1·39 
(1·24–1·55) for cardiovascular mortality (appendix p 11). 
Individuals with HCV and HIV co-infection had a higher 
risk of cardiovascular disease than those with HIV mono-
infection (RR 1·20, 1·09–1·32). Post-hoc analyses showed 
that the RR estimates from studies published before 
2014, which was the median publication year, were 
marginally higher than those from studies published 
Cohort 
name
Country or 
region
Study 
type
Data source Participants, 
n
Events, 
n
Men, n 
(%) 
Mean age 
at baseline, 
years
Study 
period
Hepatitis C 
virus status
Outcome Outcome 
definition
(Continued from previous page)
Forde et al, 
201253
THIN UK Cohort 
study
General practice 
medical records
76 477 264 46 727 
(61%)
38·6 1996–2008 Undefined Myocardial 
infarction
Read 
diagnostic 
code
Lee et al, 
201254
REVEAL–
HCV
Taiwan Cohort 
study
Questionnaires and 
interviews
19 636 477 9523 
(48%)
47·6 1991–2008 Viraemic Cardiovascular 
disease
ICD-9
Liao et al, 
201255
NHIRD Taiwan Cohort 
study
National Health 
Insurance Research 
Database
20470 1981 10235 
(50%)
52 2002–08 Viraemic Stroke ICD-9
Freiberg et al, 
201156
Veterans 
Aging 
Cohort 
Study–
virtual 
cohort
USA Cohort 
study
Veterans Aging Cohort 
Study and Large Health 
Study of Veteran 
Enrollees
8579 194 8579 
(100%)
48·1 2000–07 Seropositive Cardiovascular 
disease*
ICD-9
Kristiansen 
et al, 201157
·· Norway Cohort 
study
Department of 
Microbiology, 
University Hospital of 
North Norway
1010 5 686 
(68%)
40 1990–2000 Seropositive Cardiovascular 
disease
ICD-10
Ohsawa et al, 
201158
KAREN Japan Cohort 
study
KAREN cohort 1077 194 682 
(63%)
60·4 2003–08 Seropositive Cardiovascular 
disease
ICD-10
Bedimo et al, 
201059
HIV Clinical 
Care 
Registry
USA Cohort 
study
Veterans Registry 19 424 1146 18 938 
(97%)
46·2 1984–2004 Viraemic Myocardial 
infarction, 
stroke* 
ICD-9
Belloso et al, 
201031
LATINA Brazil, 
Mexico
Cohort 
study
LATINA cohort 160 40 Not 
reported
Not 
reported
1997–2007 Seropositive Cardiovascular 
disease*
Physician 
diagnosis
DAD Study 
Group, 201060
DAD study Europe, 
USA, 
Australia
Cohort 
study
DAD cohort 21 815 517 16 143 
(74%)
38 1999–2007 Seropositive Myocardial 
infarction*
WHO 
MONICA 
Project
Lee et al, 
201061
·· Taiwan Cohort 
study
National Death 
Certification Registry
23 665 22 11 879 
(50%)
47·1 1991–92 Viraemic Stroke ICD-9
Tsui et al, 
200932
The Heart 
and Soul 
study
USA Cohort 
study
Veterans 
Administration 
electronic records
981 151 803 
(82%)
66·3 2000–06 Seropositive Cardiovascular 
disease
Physician 
diagnosis
Guiltinan et al, 
200862
·· USA Cohort 
study
Blood Systems 20 518 88 13 254 
(65%)
Not 
reported
1991–2002 Seropositive Cardiovascular 
disease
ICD-9 CM, 
ICD-10 CM
Kalantar-
Zadeh et al, 
200763
·· USA Cohort 
study
DaVita outpatient 
dialysis database
13 664 NR 7433 
(54%)
60·1 2001–04 Seropositive Cardiovascular 
disease
Undefined
Arcari et al, 
200664
·· USA Case-
control 
study
Clinical registry 75 834 292 47 775 
(63%)
40·2 1991–2000 Seropositive Myocardial 
infarction
ICD-9
Amin et al, 
20067
·· Australia Cohort 
study
New South Wales 
Health Department 
Notifiable Diseases 
Database
582 450 582 
(100%)
34 1990–2002 Seropositive Cardiovascular 
disease
ICD-9 and 
ICD-10
ICD=International Classification of Diseases. ERCHIVES=Electronically Retrieved Cohort of Hepatitis C Virus Infected Veterans. DOPPS=Dialysis Outcomes and Practice Patterns Study. NHIRD–HCV=National Health 
Insurance Research Database–Hepatitis C Virus. ORD=Optum Research Database. OCS=Ontario HIV Treatment Network Cohort Study. UAMS=University of Arkansas for Medical Sciences. LHID2000=Longitudinal 
Health Insurance Database 2000. NR=not reported. NHANES III=National Health and Nutrition Examination Survey III. APROCO-COPILOTE=Antiprotéases Cohorte. THIN=The Health Improvement Network. 
REVEAL–HCV=Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–Hepatitis C Virus. DAD=Data Collection on Adverse Events of Anti-HIV Drugs. MONICA=Multinational Monitoring of 
Trends and Determinants in Cardiovascular Disease. CM=Clinical Modification. *Risk ratio reported for hepatitis C virus and HIV co-infection versus HIV infection only. †Australia, Belgium, Canada, mainland 
China, France, Germany, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Italy, Japan, New Zealand, Spain, Russia, Sweden, Turkey, the UK, and the USA.
Table: Baseline characteristics of studies included in the meta-analysis
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Figure 2: Forest plots of pooled RRs for cardiovascular disease in people with hepatitis C virus versus people without 
Pooled RRs for composite cardiovascular events (A), myocardial infarction (B), and stroke (C). n=number of events. N=number of participants. RR=risk ratio. NR=not 
reported. df=degrees of freedom. DAD=Data Collection on Adverse Events of Anti-HIV Drugs.
A Cardiovascular events
RR (95% CI)n/N
Amin et al (2006)7
Kalantar-Zadeh et al (2007)63
Guiltinan et al (2008)62
Tsui et al (2009)32
Belloso et al (2010)31
Freiberg et al (2011)56
Freiberg et al (2011)56
Kristiansen et al (2011)57
Ohsawa et al (2011)58
Lee et al (2012)54
Carrieri et al (2012)52
Younossi et al (2013)50
Younossi et al (2013)50
Gillis et al (2014)41
Tripathi et al (2014)46
Womack et al (2014)47
Fernandez-Montero et a (2015)39
Vajdic et al (2015)41
Piazza et al (2016)38
Goodkin et al (2017)30
Chew et al (2017)36
Kovari et al (2017)37
Heo et al (2018)33
Pooled (I2=59·9%)
450/75834
NR/13664
88/20518
1284/13 632
122/29 571
1·30 (1·20–1·50)
1·14 (0·94–1·36)
2·21 (1·41–3·46)
1·74 (0·92–3·32)
2·64 (0·65–10·80)
1·15 (0·77–1·71)
1·60 (1·03–2·48)
1·18 (0·38–2·74)
1·33 (0·84–2·11)
1·53 (1·05–2·23)
1·16 (0·59–2·29)
3·34 (0·55–20·50)
0·71 (0·23–2·21)
1·44 (0·97–2·13)
1·32 (1·08–1·61)
1·10 (0·98–1·22)
2·91 (1·19–7·12)
1·40 (0·90–1·90)
8·77 (1·10–15·32)
1·10 (0·60–2·00)
0·96 (0·90–1·02)
0·90 (0·60–1·34)
1·40 (0·97–2·02)
1·28 (1·15–1·42)
B Myocardial infarction
Arcari et al (2006)64
Bedimo et al (2010)59
DAD study group (2010)60
Forde et al (2012)53
Campbell et al (2012)51
Enger et al (2014)42
Pothineni et al (2014)45
Hsu et al (2014)44
Tsai et al (2015)40
Butt et al (2017)35
Butt et al (2017)35
Butt et al (2017)35
Goodkin et al (2017)30
Pooled (I²=77·6%)
278/19 424
517/21 815
264/76 477
423/90 931
951/16 233
848/69 915
776/15 026
0·94 (0·52–1·68)
1·25 (0·98–1·61)
0·86 (0·62–1·19)
1·10 (0·67–1·83)
3·94 (1·00–15·50)
0·94 (0·73–1·20)
1·95 (1·53–2·50)
0·95 (0·38–2·37)
1·25 (1·03–1·51)
0·93 (0·87–0·99)
1·13 (1·02–1·25)
1·19 (1·03–1·38)
1·05 (0·88–1·25)
1·13 (1·00–1·28)
C Stroke
1·0 3·0 3·52·00·5
Bedimo et al (2010)59
Lee et al (2010)61
Lee et al (2010)61
Liao et al (2012)55
Adinolfi et al (2013)48
Hsu et al (2013)50
Enger et al (2014)42
Hsu et al (2014)44
Goodkin et al (2017)30
Alvaro-Meca et al (2017)34
Alvaro-Meca et al (2017)34
Alvaro-Meca et al (2017)34
Alvaro-Meca et a (2017)34
Pooled (I²=75·3%)
Overall (df=46; I²=77·5%)
46/4091
77/4091
93/4091
153/4091
1·0 3·0 3·52·00·5
1·0 3·0 3·52·00·5
1·20 (1·04–1·38)
2·36 (1·42–3·93)
2·82 (1·25–6·37)
1·22 (1·13–1·40)
2·04 (1·69–2·46)
1·23 (1·06–1·42)
1·76 (1·23–2·52)
0·91 (0·32–2·65)
1·08 (0·92–1·27)
1·24 (0·51–3·05)
1·09 (0·59–2·00)
1·48 (0·90–2·43)
1·06 (0·73–1·53)
1·38 (1·19–1·60)
1·28 (1·18–1·39)
151/981
40/160
129/8579
65/8579
5/1010
194/1077
477/19 636
49/1154
NR/701
NR/8284
167/4152
86/2187
29/1066
19/143
6790/76 689
11 753/168 256
143/5006
117/2728
292/582
32/4068
230/7055
3489/112 652
1684/44 048
2208/76 689
868/19 424
16/23 665
6/23 665
1981/20 470
123/820
NR/15 565
111/90 931
2074/76 689
199/7055
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after 2014 (1·39 [1·25–1·54] vs 1·22 [1·11–1·34]). Studies 
that ascertained outcome with physician diagnosis had 
higher RRs than did those that used International 
Classification of Diseases codes (1·68 [1·24–2·29] vs 
1·31 [1·20–1·42]). Nine studies in patients with HCV 
viraemia had marginally higher RRs than the overall 
pooled RR (1·32, 1·15–1·51). Nearly two-thirds of studies 
originated from the USA or Taiwan (21 [58%] of 
36 studies). In the subgroup analysis, studies from these 
two countries had a similar pooled RR as those from the 
rest of the world (1·28 [1·16–1·40] vs 1·29 [1·12–1·48] 
respectively).
There was significant heterogeneity (I²=77·5%) and 
publication bias in the overall estimate (Egger’s test 
p=0·003). Using the trim and fill method to correct for 
funnel plot asymmetry did not change the direction of 
effect but did attenuate the effect size (appendix p 20). 
11 studies were at moderate or high risk of bias (appendix 
pp 12, 13). Compared with studies with a low risk of bias, 
those with moderate or high risk of bias had a similar 
pooled RR (1·30 [95% CI 1·10–1·55] for studies with 
moderate or high risk of bias vs 1·29 [1·19–1·40] for 
studies with low risk of bias). 
We estimated that in 2015, 1·5 million (95% CI 
0·9–2·1) DALYs from cardiovascular disease were 
attributable to HCV, with marked geographical 
variation in the estimated burden. LMICs had the 
highest disease burden, with South Asia, eastern 
Europe, north Africa, and the Middle East accounting 
for nearly two-thirds of the global burden of 
cardiovascular disease attributable to HCV in 2015 
(920·7 thousand DALYs; appendix p 14).
Of the 100 countries with available age-specific and 
sex-specific viraemic HCV prevalence estimates for 
2015, the highest burden (ie, cardiovascular DALYs 
attributable to HCV) was in Ukraine, Mongolia, Gabon, 
and Egypt (figure 3; appendix pp 15–17). Worldwide, the 
PAF of cardiovascular disease attributable to HCV was 
highest in people aged 55–59 years (appendix p 18). 
DALYs from cardiovascular disease attributable to HCV 
was highest in people aged 70–74 years (appendix p 18). 
The burden of cardiovascular disease attributable to 
HCV was higher in LMICs than in high-income 
countries (1·4 million [95% CI 0·88–1·95] DALYs vs 
0·1 million [95% CI 0·07–0·12] DALYs; figure 4; 
appendix p 19).
Figure 3: DALYs per 100 000 people for cardiovascular disease attributable to HCV
Grey colour denotes regions for which no HCV prevalence data were available to estimate burden. HCV=hepatitis C virus. DALYs=disability-adjusted life-years.
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Figure 4: DALYs for cardiovascular disease attributable to hepatitis C virus
Solid lines show the central estimate and dashed lines show the 95% CI. DALYs=disability-adjusted life-years.
0 20
Age (years)
0
100
DA
LY
s (
th
ou
sa
nd
s)
200
300
30 40 50 60 70 80
Low-income and middle-income countries
High-income countries
Articles
www.thelancet.com/gastrohep   Vol 4   October 2019 801
Discussion
In this systematic review and meta-analysis, we assessed 
the association between HCV and cardiovascular disease 
and estimated the global, regional, and national burden 
of cardiovascular disease attributable to HCV. We made 
several key observations. First, people with HCV have an 
increased risk of cardiovascular disease compared with 
those without HCV (RR 1·28). When stratified by type of 
cardiovascular event, the overall pooled estimate was 
higher for stroke than for myocardial infarction. Second, 
our pooled risk estimate was derived from 341 739 people 
with HCV infection included in 36 studies from 
51 countries. Only two studies30,31 reported findings from 
populations of LMICs, highlighting the paucity of data 
from these regions. Third, the most up-to-date annual 
global burden of cardiovascular disease attributable to 
HCV was 1·5 million DALYs. Most of this burden was 
concentrated in the 55–75 year age group, reflecting 
more premature development of cardiovascular disease 
in people with HCV. Fourth, considerable geographical 
variation was identified in the burden of cardiovascular 
disease attributable to HCV, with the highest burden 
observed in south Asia, eastern Europe, north Africa, and 
the Middle East. The majority of the burden was borne by 
LMICs rather than high-income countries. This 
observation is likely to reflect both a high prevalence of 
chronic hepatitis C in these regions and an increasing 
burden of cardiovascular disease.
Our analysis has several strengths. We included 
longitudinal studies that evaluated the association 
between HCV and hospital admissions with, or mortality 
from, cardiovascular disease. Furthermore, the endpoint 
of our analysis was major adverse cardiovascular events, 
which enabled accurate risk estimation and assessment 
of cardiovascular burden. Previous systematic reviews 
and meta-analyses,65–67 which included cross-sectional 
studies and studies that used surrogate endpoints that 
might not be fully reflective of a causal relationship, have 
reported divergent findings. We also analysed burden 
using age-specific, sex-specific, and country-specific 
cardiovascular burden and HCV prevalence estimates, 
allowing us to provide HCV attributable burden estimates 
for specific age groups, which could be useful for policy 
makers. Moreover, our estimates for HCV prevalence 
obtained from the Polaris Observatory23 reflect viraemia 
rather than just seropositivity alone, and the countries 
for which we had prevalence estimates accounted for 
over 89% of all chronic HCV infections globally. Our 
estimates for the PAF and subsequent HCV associated 
cardiovascular burden are therefore based on a high-risk 
population with active HCV infection, in whom both 
long-term hepatic and extrahepatic complications remain 
common.
This study has a number of limitations. Most studies 
included in this meta-analysis originated from high-
income countries in North America and western Europe, 
but estimates were applied to all regions. This approach 
is commonly used in this type of analysis because of 
paucity of data from LMICs.68,69 This highlights an 
ongoing need for research in these low-resource settings, 
in which the disease prevalence of HCV and cardio-
vascular disease is high, to improve the accuracy of the 
burden estimates in these regions. We also observed 
significant heterogeneity in our RR estimates. However, 
the direction of effect was consistent and robust across 
all subgroup analyses. The observed heterogeneity is 
likely to reflect the diverse patient population, viraemic 
status of the study population, differences in health-care 
systems, access to treatment, and geographical location 
of the studies pooled in this analysis. Many studies did 
not fully account for the competing risk of non-
cardiovascular mortality, thus some methodological 
heterogeneity exists. Most people with HCV infection die 
from non-cardiovascular causes,7,70 therefore this is an 
important competing risk that might distort the 
exposure–outcome association with cardiovascular 
disease. People with HIV and HCV co-infection have a 
higher risk for cardiovascular disease than those with 
HIV mono-infection. This increased risk highlights the 
importance of risk stratifi cation in this patient population 
considering that people with HIV are twice as likely to 
have cardiovascular events than those without HIV.22 
Although most studies evaluating the RR of cardio-
vascular disease adjusted for risk factors for cardio-
vascular disease, a substantial possibility of residual con-
founding remains. Furthermore, there was substantial 
publication bias in the literature, which might have 
influenced the risk estimates. However, there was little 
attenuation of the RRs when analysis was restricted to 
studies without moderate to high risk of bias or after 
accounting for publication bias using the trim and fill 
method. Additionally, we pooled RR estimates of 
myocardial infarction or stroke to estimate the PAF and 
combined this with the DALYs for ischaemic heart 
disease and cerebrovascular disease to estimate the 
burden of cardiovascular disease attributable to HCV. We 
were unable to estimate the burden of angina or 
peripheral artery disease attributable to HCV since these 
conditions are often diagnosed in the outpatient setting 
and are less likely to be captured by electronic health 
record systems. Therefore, it is possible that we have 
underestimated the cardiovascular burden associated 
with HCV. However, the 2010 Global Burden of Disease 
study24,71 showed that angina and peripheral artery disease 
contributed a relatively small proportion of the overall 
cardiovascular disease burden. The studies included in 
this meta-analysis are likely to be exposed to a degree of 
outcome misclassification bias because most studies 
used routine diagnostic coding to define cardiovascular 
events rather than clinical adjudication. All of the 
included studies were observational studies, and thus we 
are unable to establish causality.
The underlying pathophysiological mechanism for the 
association between HCV and cardiovascular disease 
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remains unclear.15 HCV infection has been associated 
with conditions such as type 2 diabetes, a well known 
cardiovascular risk factor.72 Evidence has emerged 
showing direct effects of HCV on the development of 
atherosclerosis,73 beyond that attributable to metabolic 
derangements alone. Chronic HCV infection results in a 
chronic state of immune stimulation and inflammation 
evidenced by increased circulating levels of proinflam-
matory cytokines, such as interleukin 6, tumour necrosis 
factor-α, C-reactive protein, and fibrinogen, all of which 
are associated with the development of atherosclerotic 
cardiovascular disease.32,74,75 Interferon-based antiviral 
treatments for HCV reduce markers of inflammation, 
endothelial dysfunction, and diabetes mellitus.76–78 
Sustained viral response with direct-acting antivirals have 
also been associated with a lower risk of cardio vascular 
events.79 Whether eradication of HCV infection reduces 
future risk of adverse cardiovascular events should be 
further explored in randomised controlled trials of direct-
acting antivirals to investigate this finding.
The link between HCV and cardiovascular disease 
has important implications for the formulation of 
health policies and resource allocation, particularly in 
regions with limited health-care resources, where 
chronic HCV infection remains prevalent and cardio-
vascular disease burden is increasing. Globally, 
prevalence of HCV is projected to increase substantially, 
particularly in LMICs, as a result of transmission via 
unsafe health-care related injections and injection drug 
use.9–11 Consequently, mortality due to hepatic and 
extrahepatic complications of HCV is likely to increase 
considerably if efforts to improve early testing and 
treatment are not implemented. A disproportionate 
burden of cardiovascular disease is borne by LMICs, 
where currently more than 80% of the global burden is 
concentrated.80 Our estimates suggest that more than 
90% of the global cardiovascular burden attributable to 
HCV occurs in LMICs.
The introduction of direct-acting antiviral therapies 
with the ability to achieve sustained virological response 
in more than 90% of treated individuals should be a cause 
for optimism. These new therapeutic options enable the 
prevention of both hepatic and extrahepatic complications 
of HCV infection with a shorter duration of treatment 
and fewer adverse events than previous generations of 
antiviral therapies. However, at present, public health 
programmes and access to health-care services for people 
with HCV lags behind other comparable infectious 
diseases, such as HIV or malaria.1 The provision of direct-
acting antiviral therapies in patients with HCV infection 
remains low on the global scale, with only one in 
15 patients1 currently being treated, the majority of whom 
reside in high-income countries.81,82 To have the greatest 
impact on HCV morbidity and mortality, the delivery of 
curative HCV treatment needs to be coupled with efficient 
health systems to provide chronic care services for 
patients with both hepatic and extrahepatic complications 
of HCV. Considering our study findings, investment in 
greater strategic integration and linkage of viral hepatitis 
services with other relevant services, including 
cardiovascular disease prevention, might be a cost-
effective method of facilitating the prevention and 
management of concurrent major health conditions. 
These innovative approaches to health-care delivery 
might require further research to evaluate feasibility and 
efficacy in a real-world clinical setting. 
People with HCV have a higher risk of developing 
cardiovascular disease than those without HCV. HCV 
accounted for 1·5 million DALYs due to cardiovascular 
disease worldwide in 2015, with the highest burden in 
South Asia, eastern Europe, north Africa, and the Middle 
East. Most of the disease burden is borne by LMICs, 
where HCV prevalence is projected to rise substantially. 
Our findings are of public health importance and could 
inform future research and health-care policies to 
improve risk stratification and treatment strategies aimed 
at reducing the combined global burden of HCV and 
extrahepatic sequelae such as cardiovascular disease.
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